Anti-Venom Market Segmentation by Species (Snake, Scorpion, Spiders, and Others); and by Anti-Venom Type (Polyvalent Anti-Venom, Monovalent Anti-Venom, and Others) – Global Demand Analysis & Opportunity Outlook 2030
Buy Now Report ID: 3755 | Published Date: Feb 07, 2023
Regionally, the global anti-venom market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of growing cases of snakebites, which require anti-venom for treatment. According to the data by the WHO, up to 2 million people are envenomed by snakes each year in Asia. Moreover, the improving healthcare sector is estimated to fuel the market growth. The market in the North America is estimated to gain significant share over the forecast period owing to the presence of major pharmaceutical companies in the region manufacturing anti-venoms. Moreover, the high awareness amongst the people in the region for the availability of such drugs is expected to boost the market growth.
Get more information on this report: Download Sample PDF
The global anti-venom market is further classified on the basis of region as follows:
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Our in-depth analysis of the global anti-venom market includes the following segments:
By Species
By Anti-Venom Type
Polyvalent Anti-venoms
Growth Drivers
Challenges
April, 2021: Rare Disease Therapeutics, Inc. announced the approval from United States (US) Food & Drug Administration (FDA) of a new expanded indication for ANAVIP, an equine-derived antivenin.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Technological innovation in the treatment for envenoming, and rising awareness about available anti-venoms, is estimated to boost the market growth.
Ans: The market is anticipated to attain a CAGR of ~7.5% over the forecast period, i.e., 2022-2030.
Ans: Absence of any regulatory measures for manufacturing anti-venom is estimated to hamper the market growth.
Ans: The market in the Asia Pacific region is projected to provide more growth opportunities over the forecast period, owing to the high incidence of snake bites and other venomous bites in the region.
Ans: The major players in the market are CSL Limited, Flynn Pharma Ltd (Micropharm), Medtoxin Venom Laboratories, Merck & Co. Inc., Pfizer Inc., Rare Disease Therapeutics Inc., Amgen Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by species, anti-venom type, and by region.
Ans: The snake segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
